Preparation of a Kit Formulation of [99mTc]Tc-CN7DM, a Mannose Derivative for Tumor Imaging, and an Exploratory Human Study.

IF 4.5 2区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Guangxing Yin, Qing Ruan, Dajie Ding, Yuhao Jiang, Peiwen Han, Qingna Xiao, Xiaoliang Chen, Junbo Zhang
{"title":"Preparation of a Kit Formulation of [<sup>99m</sup>Tc]Tc-CN7DM, a Mannose Derivative for Tumor Imaging, and an Exploratory Human Study.","authors":"Guangxing Yin, Qing Ruan, Dajie Ding, Yuhao Jiang, Peiwen Han, Qingna Xiao, Xiaoliang Chen, Junbo Zhang","doi":"10.1021/acs.molpharmaceut.5c00437","DOIUrl":null,"url":null,"abstract":"<p><p>Lung cancer is the most prevalent malignancy worldwide in terms of both incidence and mortality. Therefore, diagnosing lung cancer early is important. Nuclear medicine imaging is an integral modality for cancer diagnosis, in which radiopharmaceuticals are essential elements. Thus, we explored the potential of the novel, previously reported <sup>99m</sup>Tc-labeled mannose derivative ([<sup>99m</sup>Tc]Tc-CN7DM) as a radiopharmaceutical with excellent performance that can be easily clinically translated for tumor imaging. However, when we used a kit formulation which was directly prepared from the ligand CN7DM for preparing [<sup>99m</sup>Tc]Tc-CN7DM, some unknown radioactive compounds were found. In order to solve this problem, in this study, we synthesized the cuprous complex [Cu(CN7DM)<sub>4</sub>]BF<sub>4</sub> for kit formulation to prepare [<sup>99m</sup>Tc]Tc-CN7DM and evaluated its biological properties and safety profile. Moreover, a preliminary imaging study was conducted with lung cancer patients, and the results demonstrated that [<sup>99m</sup>Tc]Tc-CN7DM allowed clear visualization of tumor lesions, giving it promising prospects for clinical application.</p>","PeriodicalId":52,"journal":{"name":"Molecular Pharmaceutics","volume":" ","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.molpharmaceut.5c00437","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Lung cancer is the most prevalent malignancy worldwide in terms of both incidence and mortality. Therefore, diagnosing lung cancer early is important. Nuclear medicine imaging is an integral modality for cancer diagnosis, in which radiopharmaceuticals are essential elements. Thus, we explored the potential of the novel, previously reported 99mTc-labeled mannose derivative ([99mTc]Tc-CN7DM) as a radiopharmaceutical with excellent performance that can be easily clinically translated for tumor imaging. However, when we used a kit formulation which was directly prepared from the ligand CN7DM for preparing [99mTc]Tc-CN7DM, some unknown radioactive compounds were found. In order to solve this problem, in this study, we synthesized the cuprous complex [Cu(CN7DM)4]BF4 for kit formulation to prepare [99mTc]Tc-CN7DM and evaluated its biological properties and safety profile. Moreover, a preliminary imaging study was conducted with lung cancer patients, and the results demonstrated that [99mTc]Tc-CN7DM allowed clear visualization of tumor lesions, giving it promising prospects for clinical application.

用于肿瘤成像的甘露糖衍生物[99mTc]Tc-CN7DM试剂盒制剂的制备及人体探索性研究
就发病率和死亡率而言,肺癌是世界上最普遍的恶性肿瘤。因此,早期诊断肺癌很重要。核医学成像是癌症诊断不可或缺的一种方式,其中放射性药物是必不可少的元素。因此,我们探索了先前报道的99mTc标记的新型甘露糖衍生物([99mTc]Tc-CN7DM)作为一种性能优异的放射性药物的潜力,这种放射性药物可以很容易地在临床转化为肿瘤成像。然而,当我们使用由配体CN7DM直接制备的试剂盒配方制备[99mTc]Tc-CN7DM时,发现了一些未知的放射性化合物。为了解决这一问题,本研究合成了亚铜配合物[Cu(CN7DM)4]BF4作为试剂盒制剂,制备了[99mTc]Tc-CN7DM,并对其生物学特性和安全性进行了评价。此外,我们对肺癌患者进行了初步的影像学研究,结果表明[99mTc]Tc-CN7DM可以清晰地显示肿瘤病变,具有良好的临床应用前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Pharmaceutics
Molecular Pharmaceutics 医学-药学
CiteScore
8.00
自引率
6.10%
发文量
391
审稿时长
2 months
期刊介绍: Molecular Pharmaceutics publishes the results of original research that contributes significantly to the molecular mechanistic understanding of drug delivery and drug delivery systems. The journal encourages contributions describing research at the interface of drug discovery and drug development. Scientific areas within the scope of the journal include physical and pharmaceutical chemistry, biochemistry and biophysics, molecular and cellular biology, and polymer and materials science as they relate to drug and drug delivery system efficacy. Mechanistic Drug Delivery and Drug Targeting research on modulating activity and efficacy of a drug or drug product is within the scope of Molecular Pharmaceutics. Theoretical and experimental peer-reviewed research articles, communications, reviews, and perspectives are welcomed.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信